Overview

TVEC and Preop Radiation for Sarcoma (4 ml Dose)

Status:
Active, not recruiting

Trial end date:
2023-10-16

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 30 people will take part in this study conducted by investigators at the University of Iowa.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Milhem, Mohammed M
University of Iowa

Collaborator:

Amgen

Treatments:

Talimogene laherparepvec